-
-
-
-
-
-
-
Alkermes (ALKS) Announces FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder (Earlier)
-
-
-
-
-
-
-
Virtual FDA Advisory Committee Meeting to Review New Drug Application for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder Tentatively Scheduled for Oct. 9, 2020
-
-
-
-
-
-
-
Pre-Open Stock Movers 1/28: (DLPH) (XLRN) (ALKS) Higher (EROS) (BWA) (DDD) Lower (more...)
-
-
-
-
-
-
-
New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis
-
-
-
-
-
-
-
Recro Pharma (REPH) Amends IV Meloxicam License Agreement with Alkermes (ALKS)
-
-
-
-
-
-
-
Alkermes (ALKS) PT Raised to $56 at Leerink Partners
-
-
-
-
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

